Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 23, 2022 11:22am

134 Views

Post# 35189520

RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

One doesn't need to go beyond posters like TitanBrawler and Quentin30 to see how employees of hedge funds and MMs have been trading to see the tactics that their employers have employed in trying to manipulate the stock price for their own benefit.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023